BlueWillow’s clinical-stage, oil-in-water emulsion adjuvant technology unlocks the promise of intranasal vaccination and immunotherapy. Compatibility with a broad range of antigens leads to vaccines that elicit the balanced mucosal, cellular and systemic immune response needed for robust and durable protection. With human safety established from multiple clinical trials, the platform is the most advanced intranasal adjuvant available today. Taking advantage of a Th1-dominant immune response, the same emulsion technology enables immunotherapy against food allergies. 



Human Safety Data

Announcements and Updates